Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events

References

• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med [Internet]. 2015;1–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26028407
   Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med [Internet]. 2015;372(21):2018–2028. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891174
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med [Internet]. 2018;379:2220–2229. Available from: 10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non–small-cell lung cancer. N Engl J Med [Internet]. 2017;377:1919–1929. Available from: 10.1056/NEJMoa1709937
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med [Internet]. 2018;379:2040–2051. Available from: 10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol [Internet]. 2015;16:257–265. Available from: https://www.sciencedirect.com/science/article/pii/S1470204515700549
   PubMed Web of Science ®Google Scholar
• Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized Phase III trial. J Thorac Oncol. 2020;15:1351–1360.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med [Internet]. 2018;378:2078–2092. Available from: 10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med [Internet]. 2018;378:2288–2301. Available from: 10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Krummel MF, and Allison JP. CD28 and CTLA-4 have opposing effects on the response of T ceils to stimulation. J Exp Med. 1995;182:459–465.
   PubMed Web of Science ®Google Scholar
• Salvi S, Fontana V, Boccardo S, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2012;61:1463–1472.
   PubMed Web of Science ®Google Scholar
• Huang PY, Guo SS, Zhang Y, et al. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. Oncotarget. 2016;7:13060.
   PubMedGoogle Scholar
• Yang C-Y, Lin M-W, Chang Y-L, et al. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer. 2016;57:91–103.
   PubMed Web of Science ®Google Scholar
• Zhou Z-J, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4:203–208.
   PubMedGoogle Scholar
• Pu N, Gao S, Yin H, et al. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Cancer Lett. 2019;460:42–53.
   PubMed Web of Science ®Google Scholar
• Du S, McCall N, Park K, et al. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. Oncoimmunology. 2018;7:e1408747.
   PubMed Web of Science ®Google Scholar
• König D, Läubli H. Mechanisms of immune-related complications in cancer patients treated with immune checkpoint inhibitors. Pharmacology. 2021;106:123–136.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. J Clin Oncol [Internet]. 2021;39:9002. Available from: 10.1200/JCO.2021.39.15_suppl.9002
   Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363 doi:https://doi.org/10.1136/bmj.k4226 Accessed 02 07 2021.
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–1546.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563–580.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected Stage III melanoma. N Engl J Med. 2018;378:1789–1801.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Diehl A, Yarchoan M, Hopkins A, et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget [Internet]. 2017;8:114268–114280. Available from: https://pubmed.ncbi.nlm.nih.gov/29371985
   PubMedGoogle Scholar
• Nakamura Y, Tanaka R, Maruyama H, et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol [Internet]. 2019;49:431–437.
   PubMed Web of Science ®Google Scholar
• Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res [Internet]. 2016 Dec 28. 2017;77:1322–1330. Available from: https://pubmed.ncbi.nlm.nih.gov/28031229
   PubMed Web of Science ®Google Scholar
• Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving Anti-PD-1–based immunotherapy. Clin Cancer Res [Internet]. 2019;25:1557. Available from: http://clincancerres.aacrjournals.org/content/25/5/1557.abstract
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol [Internet]. 2017;28:1368–1379. Available from: https://www.sciencedirect.com/science/article/pii/S0923753419324317
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer [Internet]. 2015;3:39. Available from: https://pubmed.ncbi.nlm.nih.gov/26380086
   PubMed Web of Science ®Google Scholar
• Von Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem [Internet]. 2020;66:779–793. Available from: https://pubmed.ncbi.nlm.nih.gov/32363387
   PubMed Web of Science ®Google Scholar
• Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci. 2017;108:1000–1006.
   PubMed Web of Science ®Google Scholar
• Felip E, Ardizzoni A, Ciuleanu T, et al. CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020;127:160–172.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, and Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1714–1768.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Abu-Sbeih H, and Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9 e002435 doi:https://doi.org/10.1136/jitc-2021-002435 Accessed 02 07 2021 .
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw J Natl Compr Canc Netw [Internet]. 2019;17:255–289. Available from: https://jnccn.org/view/journals/jnccn/17/3/article-p255.xml
   PubMed Web of Science ®Google Scholar
• Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. 2020;369:m736.
   PubMedGoogle Scholar
• Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145:639–648.
   PubMed Web of Science ®Google Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345–361.
   PubMed Web of Science ®Google Scholar
• Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2746–2758.
   PubMed Web of Science ®Google Scholar
• Wang F-P, Tang X-J, Wei C-Q, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90:190–198.
   PubMed Web of Science ®Google Scholar
• Zhao Z-T, Ji C-M, Yu W-J, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742–1750.e4.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173–182.
   PubMed Web of Science ®Google Scholar
• Brancatella A, Viola N, Brogioni S, et al. Graves’ disease induced by immune checkpoint inhibitors: a case report and review of the literature. Eur Thyroid J. 2019;8:192–195.
   PubMed Web of Science ®Google Scholar
• Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1.
   PubMedGoogle Scholar
• Akturk H Kaan and Michels A W. (2020). Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Current Opinion in Endocrinology, Diabetes & Obesity, 27(4), 187–193. https://doi.org/10.1097/MED.0000000000000546
   PubMedGoogle Scholar
• Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol [Internet]. 2021;14:45. Available from: 10.1186/s13045-021-01056-8
   PubMed Web of Science ®Google Scholar
• Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20:e9.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020–2031.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6:103.
   PubMed Web of Science ®Google Scholar
• Diana P, Mankongpaisarnrung C, Atkins M B, Zeck J C and Charabaty A. (2018). Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. ACG Case Reports Journal, 5(1), e17 https://doi.org/10.14309/crj.2018.17
   PubMedGoogle Scholar
• Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer [Internet]. 2019;7:319. Available from: 10.1186/s40425-019-0774-y
   PubMed Web of Science ®Google Scholar
• Fisher J, Zeitouni N, Fan W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol. 2020;82:1490–1500.
   PubMed Web of Science ®Google Scholar
• Ijaz A, Khan AY, Malik SU, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25:94–99.
   PubMed Web of Science ®Google Scholar
• Khan SA, Pruitt SL, Xuan L, et al. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2:1507–1508.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:368–376.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234–240.
   PubMed Web of Science ®Google Scholar
• Boland P, Pavlick AC, Weber J, et al. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immun-other Cancer. 2020;8 e000356 doi:https://doi.org/10.1136/jitc-2019-000356 Accessed 30 12 2021 .
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med [Internet]. 2015;373:1627–1639. Available from: 10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar